These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 20149931)

  • 1. Rapamycin inhibits relapsing experimental autoimmune encephalomyelitis by both effector and regulatory T cells modulation.
    Esposito M; Ruffini F; Bellone M; Gagliani N; Battaglia M; Martino G; Furlan R
    J Neuroimmunol; 2010 Mar; 220(1-2):52-63. PubMed ID: 20149931
    [TBL] [Abstract][Full Text] [Related]  

  • 2. IL-10 is involved in the suppression of experimental autoimmune encephalomyelitis by CD25+CD4+ regulatory T cells.
    Zhang X; Koldzic DN; Izikson L; Reddy J; Nazareno RF; Sakaguchi S; Kuchroo VK; Weiner HL
    Int Immunol; 2004 Feb; 16(2):249-56. PubMed ID: 14734610
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Autoantigen-specific immunosuppression with tolerogenic peripheral blood cells prevents relapses in a mouse model of relapsing-remitting multiple sclerosis.
    Kleist C; Mohr E; Gaikwad S; Dittmar L; Kuerten S; Platten M; Mier W; Schmitt M; Opelz G; Terness P
    J Transl Med; 2016 May; 14(1):99. PubMed ID: 27131971
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A synthetic androstene derivative and a natural androstene metabolite inhibit relapsing-remitting EAE.
    Offner H; Zamora A; Drought H; Matejuk A; Auci DL; Morgan EE; Vandenbark AA; Reading CL
    J Neuroimmunol; 2002 Sep; 130(1-2):128-39. PubMed ID: 12225895
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment with rapamycin ameliorates clinical and histological signs of protracted relapsing experimental allergic encephalomyelitis in Dark Agouti rats and induces expansion of peripheral CD4+CD25+Foxp3+ regulatory T cells.
    Donia M; Mangano K; Amoroso A; Mazzarino MC; Imbesi R; Castrogiovanni P; Coco M; Meroni P; Nicoletti F
    J Autoimmun; 2009 Sep; 33(2):135-40. PubMed ID: 19625166
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glatiramer acetate reduces Th-17 inflammation and induces regulatory T-cells in the CNS of mice with relapsing-remitting or chronic EAE.
    Aharoni R; Eilam R; Stock A; Vainshtein A; Shezen E; Gal H; Friedman N; Arnon R
    J Neuroimmunol; 2010 Aug; 225(1-2):100-11. PubMed ID: 20554028
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of relapsing experimental autoimmune encephalomyelitis in SJL mice by feeding the immunodominant PLP139-151 peptide.
    Karpus WJ; Kennedy KJ; Smith WS; Miller SD
    J Neurosci Res; 1996 Aug; 45(4):410-23. PubMed ID: 8872901
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Eluding anaphylaxis allows peptide-specific prevention of the relapsing stage of experimental autoimmune encephalomyelitis.
    Wegmann KW; Archie Bouwer HG; Whitham RH; Hinrichs DJ
    J Neuroimmunol; 2014 Sep; 274(1-2):46-52. PubMed ID: 24997489
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Decreased severity of experimental autoimmune encephalomyelitis during resveratrol administration is associated with increased IL-17+IL-10+ T cells, CD4(-) IFN-gamma+ cells, and decreased macrophage IL-6 expression.
    Imler TJ; Petro TM
    Int Immunopharmacol; 2009 Jan; 9(1):134-43. PubMed ID: 19022403
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rapamycin relieves inflammation of experimental autoimmune encephalomyelitis by altering the balance of Treg/Th17 in a mouse model.
    Li Z; Nie L; Chen L; Sun Y; Li G
    Neurosci Lett; 2019 Jul; 705():39-45. PubMed ID: 31004709
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-IL-16 therapy reduces CD4+ T-cell infiltration and improves paralysis and histopathology of relapsing EAE.
    Skundric DS; Dai R; Zakarian VL; Bessert D; Skoff RP; Cruikshank WW; Kurjakovic Z
    J Neurosci Res; 2005 Mar; 79(5):680-93. PubMed ID: 15682385
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early pregnancy factor suppresses experimental autoimmune encephalomyelitis induced in Lewis rats with myelin basic protein and in SJL/J mice with myelin proteolipid protein peptide 139-151.
    Zhang B; Harness J; Somodevilla-Torres MJ; Hillyard NC; Mould AW; Alewood D; Love SG; Alewood PF; Greer JM; Cavanagh AC; McCombe PA; Morton H
    J Neurol Sci; 2000 Dec; 182(1):5-15. PubMed ID: 11102634
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Controlled Delivery of Single or Multiple Antigens in Tolerogenic Nanoparticles Using Peptide-Polymer Bioconjugates.
    Pearson RM; Casey LM; Hughes KR; Wang LZ; North MG; Getts DR; Miller SD; Shea LD
    Mol Ther; 2017 Jul; 25(7):1655-1664. PubMed ID: 28479234
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination treatment of mice with CRx-153 (nortriptyline and desloratadine) decreases the severity of experimental autoimmune encephalomyelitis.
    Podojil JR; Padval MV; Miller SD
    Cell Immunol; 2011; 270(2):237-50. PubMed ID: 21696712
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rapamycin, not cyclosporine, permits thymic generation and peripheral preservation of CD4+ CD25+ FoxP3+ T cells.
    Coenen JJ; Koenen HJ; van Rijssen E; Kasran A; Boon L; Hilbrands LB; Joosten I
    Bone Marrow Transplant; 2007 May; 39(9):537-45. PubMed ID: 17351648
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination of apoptotic T cell induction and self-peptide administration for therapy of experimental autoimmune encephalomyelitis.
    Kasagi S; Wang D; Zhang P; Zanvit P; Chen H; Zhang D; Li J; Che L; Maruyama T; Nakatsukasa H; Wu R; Jin W; Sun L; Chen W
    EBioMedicine; 2019 Jun; 44():50-59. PubMed ID: 31097410
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tolerogenic nanoparticles suppress central nervous system inflammation.
    Kenison JE; Jhaveri A; Li Z; Khadse N; Tjon E; Tezza S; Nowakowska D; Plasencia A; Stanton VP; Sherr DH; Quintana FJ
    Proc Natl Acad Sci U S A; 2020 Dec; 117(50):32017-32028. PubMed ID: 33239445
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of gut commensal microflora in the development of experimental autoimmune encephalomyelitis.
    Ochoa-Repáraz J; Mielcarz DW; Ditrio LE; Burroughs AR; Foureau DM; Haque-Begum S; Kasper LH
    J Immunol; 2009 Nov; 183(10):6041-50. PubMed ID: 19841183
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CD4+CD25+FoxP3+PD1- regulatory T cells in acute and stable relapsing-remitting multiple sclerosis and their modulation by therapy.
    Saresella M; Marventano I; Longhi R; Lissoni F; Trabattoni D; Mendozzi L; Caputo D; Clerici M
    FASEB J; 2008 Oct; 22(10):3500-8. PubMed ID: 18587005
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Substrain differences reveal novel disease-modifying gene candidates that alter the clinical course of a rodent model of multiple sclerosis.
    deLuca LE; Pikor NB; O'Leary J; Galicia-Rosas G; Ward LA; Defreitas D; Finlay TM; Ousman SS; Osborne LR; Gommerman JL
    J Immunol; 2010 Mar; 184(6):3174-85. PubMed ID: 20173032
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.